Almirall, S.A.
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Almirall, S.A. sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Almirall, S.A.: 19 sponsored US clinical trials, 1 recruiting.
Almirall, S.A. sponsors 19 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 18 completed. 9 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 2 trials.
Top-decile sponsor footprint
Almirall, S.A. ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
19 total, page 1 of 1
A Study of LAD603 in Adults With Alopecia Areata
NCT07311564
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects
NCT06200597
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
NCT06488209
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
NCT05279131
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
NCT05260073
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
NCT04820673
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
NCT03285477
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
NCT03285490
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
NCT02959970
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
NCT02838628
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
NCT02413346
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
NCT02320149
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
NCT02322866
Photoallergy Potential of Dapsone Gel in Healthy Volunteers
NCT02117739
Dermal Tolerability of Dapsone Gel in Healthy Volunteers
NCT02117752
Phototoxicity Test of Dapsone Gel in Healthy Volunteers
NCT02108483
Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
NCT01974323
A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
NCT01974141
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
NCT01628549
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Almirall, S.A. pipeline
1 recruiting of 19 indexed (5% open); 18 completed (95%).
Phase mix: 9 late (III/IV) vs 8 early (I/II) (balanced across stages).
Top condition: Acne Vulgaris (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Almirall, S.A.: open-pipeline peers nationwide
Peers matched on 19 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Almirall, S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 trials (± recruiting share)
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
- Defense and Veterans Center for Integrative Pain Management · 19 trials · 5% recruiting
Sponsors near 5% open enrollment (± trial volume)
- DePuy Orthopaedics · 5% recruiting · 38 trials
- Impax Laboratories · 5% recruiting · 19 trials
- Kent State University · 5% recruiting · 19 trials
- Omeros Corporation · 5% recruiting · 19 trials
Related
What to do with this Almirall, S.A. page
19 registered trials is a research-attention snapshot, not an endorsement of Almirall, S.A. or any single study.
- 1 of Almirall, S.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Almirall, S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Almirall, S.A. pipeline card: 19 registered trials from official public datasets.Report a data error.